Research records indexed for Orforglipron
This page carries 12 of the 140 records that the literature query returned for Orforglipron, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 128 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Orforglipron.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial pmid:41765029 | 2026 | Clinical Trial, Phase III, Comparative Study | human trial | Not stated | Indexed as clinical trial, phase iii, comparative study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Fluorine Compounds; Oxadiazoles; Hypoglycemic Agents; Administration, Oral. |
| Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial pmid:41275875 | 2026 | Clinical Trial, Phase III, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase iii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Obesity; Fluorine Compounds; Oxadiazoles; Hypoglycemic Agents. |
| Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial pmid:42120723 | 2026 | Clinical Trial, Phase III, research-article | human trial | Not stated | Indexed as clinical trial, phase iii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Obesity; Weight Loss; Fluorine Compounds; Oxadiazoles; Glucagon-Like Peptides. |
| Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes pmid:41683830 | 2026 | review-article, Review | other | Not stated | Indexed as review-article, review. study model from MeSH "Animals" with no rodent species heading. subject headings: Diabetes Mellitus, Type 2; Obesity; Fluorine Compounds; Oxadiazoles; Hypoglycemic Agents. |
| Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight pmid:41994902 | 2026 | research-article, Multicenter Study | human trial | Not stated | Indexed as research-article, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase i". subject headings: Obesity; Fluorine Compounds; Oxadiazoles; Anti-Obesity Agents; Capsules. |
| A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes pmid:41325139 | 2026 | research-article, Clinical Trial, Phase I | human trial | Not stated | Indexed as research-article, clinical trial, phase i. study model from MeSH "Humans" with publication type "clinical trial, phase i". subject headings: Diabetes Mellitus, Type 2; Fluorine Compounds; Oxadiazoles; Blood Glucose; Hypoglycemic Agents. |
| Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants pmid:40888509 | 2026 | Research Support, Non-U.S. Gov't, Clinical Trial, Phase I | human trial | Not stated | Indexed as research support, non-u.s. gov't, clinical trial, phase i. study model from MeSH "Humans" with publication type "clinical trial, phase i". subject headings: Fluorine Compounds; Oxadiazoles; Administration, Oral; Biological Availability; Healthy Volunteers. |
| Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial pmid:42259339 | 2026 | Clinical Trial, Phase III, Comparative Study | human trial | Not stated | Indexed as clinical trial, phase iii, comparative study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Fluorine Compounds; Metformin; Benzhydryl Compounds; Oxadiazoles. |
| Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials pmid:42338042 | 2026 | Clinical Trial, Phase III, research-article | human trial | Not stated | Indexed as clinical trial, phase iii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Liver; Diabetes Mellitus, Type 2; Obesity; Fluorine Compounds; Benzhydryl Compounds. |
| Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison pmid:42225305 | 2026 | Comparative Study, research-article | other | Not stated | Indexed as comparative study, research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Obesity; Weight Loss; Fluorine Compounds; Oxadiazoles; Anti-Obesity Agents. |
| Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning pmid:42138103 | 2026 | Review | other | Not stated | Indexed as review. study model from MeSH "Animals" with no rodent species heading. subject headings: Obesity; Weight Loss; Fluorine Compounds; Oxadiazoles; Anti-Obesity Agents. |
| Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis pmid:41640110 | 2026 | Meta-Analysis, Systematic Review | other | Not stated | Indexed as meta-analysis, systematic review. study model from MeSH "Humans" with no interventional publication type. subject headings: Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Fluorine Compounds. |
Where this page sits
Compound page: Orforglipron. Class: Incretin receptor agonists.
Retrieved 2026-10-12.
Sources
- PubChem Compound Summary for CID 137319706, Orforglipron. PubChem, National Library of Medicine (2026). pubchem:137319706
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA220934. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:orforglipron
- Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proceedings of the National Academy of Sciences of the United States of America (2020). pmid:33177239
- The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Science translational medicine (2024). pmid:39693407
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes, obesity & metabolism (2023). pmid:37344954
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes, obesity & metabolism (2023). pmid:37264711
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. The New England journal of medicine (2023). pmid:37351564
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet (London, England) (2023). pmid:37369232
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. The New England journal of medicine (2025). pmid:40544435
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. The New England journal of medicine (2025). pmid:40960239
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet (London, England) (2026). pmid:41765029
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.